FATE THERAPEUTICS INC (28)

Browse by Contract Category

Contracts

License Agreement, dated April 9, 2020, by and between the Registrant and Dana-Farber Cancer Institute, Inc (Filed With SEC on February 28, 2022)
Open Market Sale AgreementSM dated November 4, 2021 by and between Fate Therapeutics, Inc. and Jefferies LLC (Filed With SEC on November 4, 2021)
Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on August 4, 2021)
Forms of Restricted Stock Unit Award Agreement under Fate Therapeutics, Inc. Inducement Equity Plan (Filed With SEC on February 24, 2021)
Lease Agreement by and between the Registrant and Scripps Summit Investments LLC, dated January 7, 2020 (Filed With SEC on March 2, 2020)
Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on February 24, 2021)
Patent License Agreement by and between the Registrant and Max-Delbrck-Centrum fr Molekulare Medizin in der Helmholtz-Gemeinschaft, dated August 30, 2019 (Filed With SEC on February 24, 2021)
Letter Agreement, dated December 4, 2020, by and between the Registrant and Ono Pharmaceutical Co., Ltd (Filed With SEC on February 24, 2021)
License Agreement between the Registrant and The Scripps Research Institute, dated as of August 24, 2010 (Filed With SEC on February 24, 2021)
License Agreement between the Registrant and The Scripps Research Institute, dated as of May 25, 2010 (Filed With SEC on February 24, 2021)
License Agreement between the Registrant and The Scripps Research Institute, dated as of July 13, 2009 (Filed With SEC on February 24, 2021)
Whitehead Institute for Biomedical Research Exclusive Patent License Agreement between the Registrant and the Whitehead Institute for Biomedical Research, dated as of February 24,... (Filed With SEC on February 24, 2021)
Forms of Stock Option Agreement under Fate Therapeutics, Inc. Inducement Equity Plan (Filed With SEC on February 24, 2021)
Fate Therapeutics, Inc. Amended and Restated Inducement Equity Plan (Filed With SEC on February 24, 2021)
Amended and Restated 2013 Stock Option and Incentive Plan and forms of agreements thereunder (Filed With SEC on February 24, 2021)
Description of Securities (Filed With SEC on February 24, 2021)
Form of Pre-Funded Warrant (Filed With SEC on January 8, 2021)
Underwriting Agreement, dated January 5, 2021 (Filed With SEC on January 8, 2021)
Offer Letter between the Company and Edward J. Dulac III, dated as of May 20, 2020 (Filed With SEC on August 19, 2020)
Underwriting Agreement, dated June 8, 2020 (Filed With SEC on June 10, 2020)
Fate Therapeutics, Inc. Inducement Equity Plan (Filed With SEC on March 2, 2020)
Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on March 2, 2020)
Description of Securities (Filed With SEC on March 2, 2020)
Underwriting Agreement, dated September 11, 2019 (Filed With SEC on September 13, 2019)
Fate Therapeutics, Inc. Inducement Equity Plan (Filed With SEC on March 5, 2019)
Offer Letter by and between the Registrant and Bahram Valamehr, dated November 23, 2009 (Filed With SEC on March 5, 2019)
Offer Letter by and between the Registrant and Cindy R. Tahl, dated October 23, 2009 (Filed With SEC on March 5, 2019)
Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on March 5, 2019)